ストックスクリーナーアプリを入手
1.44
9.32%
-0.148
アフターアワーズ：
1.43
-0.01
-0.69%
前日終値:
$1.588
開ける：
$1.58
24時間の取引高:
127.84K
Relative Volume:
1.36
時価総額：
$66.21M
収益：
$84.32M
当期純損益:
$-3.16M
株価収益率:
-28.80
EPS:
-0.05
ネットキャッシュフロー:
$-4.50M
1週間 パフォーマンス:
-16.76%
1か月 パフォーマンス:
-20.00%
6か月 パフォーマンス:
+1.41%
1年 パフォーマンス:
-16.76%
1日の値動き範囲:
$1.42
$1.58
1週間の範囲:
$1.42
$1.7577
52週間の値動き範囲:
$1.08
$2.18
Theratechnologies Inc Stock (THTX) Company Profile
THTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
THTX
Theratechnologies Inc
|
1.44 | 66.21M | 84.32M | -3.16M | -4.50M | -0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Theratechnologies Inc Stock (THTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-11-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-07-29 | ダウングレード | Canaccord Genuity | Buy → Hold |
Theratechnologies Inc (THTX) 最新ニュース
Theratechnologies (TSE:TH) Stock Passes Above 50-Day Moving AverageShould You Sell? - MarketBeat
Theratechnologies (NASDAQ:THTX) Shares Down 0.6%Time to Sell? - MarketBeat
Theratechnologies (NASDAQ:THTX) Shares Down 0.6% – Time to Sell? - Defense World
Theratechnologies (NASDAQ:THTX) Trading Down 0.6% – Time to Sell? - Defense World
Theratechnologies (TSE:TH) Stock Price Crosses Above 50-Day Moving AverageShould You Sell? - MarketBeat
World Orphan Drug Alliance expands to Canada and full LATAM region, completing the first truly global commercialization offering - GlobeNewswire Inc.
Impending Shortage of Theratechnologies’ EGRIFTA SV® Amid Manufacturing Shutdown - TipRanks
Theratechnologies issues update on Egrifta SV shortage (THTX:NASDAQ) - Seeking Alpha
Theratechnologies Warns of Upcoming Shortage for HIV-Induced Stomach Fat Treatment - MarketWatch
Theratechnologies Provides Update on EGRIFTA SV® Supply - GlobeNewswire
Theratechnologies (TSE:TH) Reaches New 52-Week HighWhat's Next? - MarketBeat
Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update - MarketBeat
Theratechnologies (TSE:TH) Stock Crosses Above Fifty Day Moving AverageHere's What Happened - MarketBeat
Theratechnologies expands rare disease portfolio with Ionis partnership - MSN
Theratechnologies Seeks FDA Approval for Manufacturing Changes to EGRIFTA SV® - TipRanks
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment - The Manila Times
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® ... - Russellville Courier
Theratechnologies Seeks FDA Approval for EGRIFTA SV® Manufacturing Changes Amid Supply Concerns - StockTitan
Financial Review: Aclaris Therapeutics (NASDAQ:ACRS) versus Theratechnologies (NASDAQ:THTX) - Defense World
Closing Bell: Theratechnologies Up On Wednesday (TH) - Barchart
Theratechnologies (TSE:TH) Stock Crosses Above 50 Day Moving AverageHere's What Happened - MarketBeat
Theratechnologies Secures Canadian Rights for Ionis RNA Medicines - TipRanks
Short Interest in Theratechnologies Inc. (NASDAQ:THTX) Decreases By 44.0% - MarketBeat
Theratechnologies Inc. Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA - Marketscreener.com
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA - GlobeNewswire
Theratechnologies Awaits FDA Decision on New EGRIFTA Formulation, Sets March 2025 PDUFA Date - StockTitan
Theratechnologies Shows Promise in Ovarian Cancer Trial - TipRanks
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer - GlobeNewswire
Theratechnologies' Cancer Drug Shows Promise: Tumor Shrinkage in Phase 1b Trial - StockTitan
Deal Watch: GSK Extends Its Shingrix Alliance In China With Zhifei - News & Insights
Theratechnologies enters exclusive licensing agreement with Ionis - Yahoo Finance
Small caps to watch: This fintech stock has doubled this past year and analysts predict further record highs ahead - The Globe and Mail
Theratechnologies expands rare disease portfolio with Ionis partnership | 2024-12-04 | Investing News - Stockhouse Publishing
Theratechnologies Expands Portfolio with Ionis Deal - TipRanks
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen - The Bakersfield Californian
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada - GlobeNewswire
Theratechnologies Secures Exclusive Rights to Two Breakthrough Rare Disease Drugs in $22.75M Deal - StockTitan
EGRIFTA SV production restarts after FDA inspection - Investing.com India
Theratechnologies resumes production of EGRIFTA SV - MSN
EGRIFTA SV production restarts after FDA inspection By Investing.com - Investing.com Nigeria
Theratechnologies resumes production of Egrifta SV - Nasdaq
Theratechnologies Announces Resumed Production of EGRIFTA SV® - GlobeNewswire
Theratechnologies Inc. Announces Resume Production of EGRIFTA SV - Marketscreener.com
Theratechnologies secures up to $75M in new credit facilities - Yahoo Finance
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec - GlobeNewswire
Theratechnologies Secures $75M Credit Facility with Improved Terms, Freeing Up $19M Cash - StockTitan
Theratechnologies resubmits BLA for new tesamorelin formulation - MSN
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review - Marketscreener.com
Theratechnologies Resubmits Tesamorelin Application to FDA - TipRanks
Theratechnologies Resubmits FDA Application for Improved HIV Treatment Formulation | THTX Stock News - StockTitan
Theratechnologies Inc (THTX) 財務データ
収益
当期純利益
現金流量
EPS
5.49%
0.79%
大文字化:
|
ボリューム (24 時間):